Advertisement
Advertisement
U.S. Markets close in 4 hrs 23 mins
Advertisement
Advertisement
Advertisement
Advertisement

SpringWorks Therapeutics, Inc. (SWTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
37.03-2.63 (-6.63%)
As of 11:36AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close39.66
Open38.66
Bid37.13 x 800
Ask37.30 x 800
Day's Range36.90 - 39.18
52 Week Range13.60 - 81.67
Volume241,627
Avg. Volume1,316,212
Market Cap1.824B
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-2.21
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est76.25
  • GlobeNewswire

    SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

    – Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors Met Its Primary and All Key Secondary Endpoints – – Encouraging Preliminary Data from Phase 1/2 Study Evaluating Nirogacestat in Combination with Low-Dose Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma Presented at ASCO; Combination Continues in Ongoing Phase 2 Trial and Expands into Additional Sub-Studies with Standard of Care Agents – – Mirdametinib Monotherapy and Comb

  • GlobeNewswire

    SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference

    STAMFORD, Conn., Aug. 02, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on Wednesday, August 10th at 10:55 a.m. ET. To access the live webcast please visit the Events & Presentations page within the Investors & Media

  • GlobeNewswire

    SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors

    STAMFORD, Conn., July 15, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Carlos Albán to the Company’s Board of Directors. Mr. Albán, who served as Vice Chairman and Chief Commercial Officer at AbbVie, Inc. (“AbbVie”) until his retirement last year, brings over 30 years of experience in global comme

Advertisement
Advertisement